US20140010846A1 - Prevention and treatment of ocular side effects with a cyclosporin - Google Patents

Prevention and treatment of ocular side effects with a cyclosporin Download PDF

Info

Publication number
US20140010846A1
US20140010846A1 US13/966,744 US201313966744A US2014010846A1 US 20140010846 A1 US20140010846 A1 US 20140010846A1 US 201313966744 A US201313966744 A US 201313966744A US 2014010846 A1 US2014010846 A1 US 2014010846A1
Authority
US
United States
Prior art keywords
therapeutically active
cyclosporin
active agent
keratoconjunctivitis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/966,744
Inventor
Gregg Feinerman
Neil Barth
Rhett Schiffman
Pamela S. Barnett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saint Regis Mohawk Tribe
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to US13/966,744 priority Critical patent/US20140010846A1/en
Publication of US20140010846A1 publication Critical patent/US20140010846A1/en
Assigned to ALLERGAN, INC. reassignment ALLERGAN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHIFFMAN, RHETT, BARNETT, PAMELA S., FEINERMAN, GREGG, BARTH, NEIL
Assigned to SAINT REGIS MOHAWK TRIBE reassignment SAINT REGIS MOHAWK TRIBE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALLERGAN, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • Patients undergoing treatment with certain therapeutically active agents can have certain ocular conditions as a result of that treatment.
  • patients undergoing chemotherapy with a therapeutically active agent effective for treatment of a cancer often have ocular conditions as a result of that treatment.
  • One embodiment is a method comprising administering a cyclosporin, an analog or derivative thereof, or a combination thereof, to an eye of a mammal in combination with administration of a therapeutically active agent to said mammal, said therapeutically active agent being an chemotherapy agent or an antiviral agent, wherein said method is effective in preventing or treating an ocular condition associated with the use of said therapeutically active agent.
  • administering means administration of the therapeutically active agent to the mammal in any way that a therapeutically active agent may be administered.
  • administration of the therapeutically active agent is not limited to the eye, but may include systemic administration via oral, intravenous, rectal, or other means; or administration locally to any part of the body by injection, implantation, topical administration, or other means.
  • Administration of the therapeutically active agent need not exactly overlap in time with the administration of the cyclosporin, an analog or derivative thereof, or a combination thereof.
  • the cyclosporin, analog or derivative thereof, or a combination thereof might be administered to a mammal before the mammal receives any of the therapeutically active agent to avoid the onset of the ocular condition.
  • the cyclosporin, analog or derivative thereof, or a combination thereof might be administered after the mammal has begun to receive the therapeutically active agent.
  • the cyclosporin, analog or derivative thereof, or a combination thereof might be administered after the mammal has ceased receiving the therapeutically active agent.
  • Administration of the cyclosporin, analog or derivative thereof, or a combination thereof might also be simultaneous with the administration of the therapeutically active agent.
  • any time relationship may exist between the mammal receiving the therapeutically active agent and the cyclosporin, analog or derivative thereof, or a combination thereof, provided that the use of the latter is reasonably related to treatment or prophylaxis of a condition associated with the former.
  • composition which comprises both (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent when the agents are to be administered simultaneously.
  • kits may be convenient to provide (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent in form of a kit.
  • the agents may be packaged together.
  • the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent may each be packaged in conventional pharmaceutical packaging such as boxes, jars, blister packs, vials, bottles, syringes etc., and the individually packaged components may then be combined to form a kit e.g. by the use of further packaging such as a box, or by joining up the individual packages.
  • kit form the agents can be taken independently of one another, thus allowing the user freedom to decide the temporal relationship between his use of each of the agents.
  • a cyclosporin, or an analog or derivative thereof, including cyclosporin A for the treatment of ocular conditions occurring in a person undergoing treatment with a therapeutically active agent for the treatment of cancer is contemplated. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of a chemotherapy agent.
  • a cyclosporin or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person who is undergoing treatment with an antiviral agent. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of an antiviral agent.
  • a cyclosporin or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person who is undergoing treatment with an immunomodulator. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of an immunomodulator.
  • Cyclosporin A is a cyclic peptide with immunosuppressive properties having the structure shown above. It is also known by other names including cyclosporine, cyclosporine A, ciclosporin, and ciclosporin A.
  • cyclosporins include cyclosporine b, cyclosporine D, cyclosporine G, which are well known in the art. Cyclosporin derivatives and analogs are also known in the art. For example, U.S. Pat. Nos. 6,254,860 and 6,350,442, incorporated by reference herein, illustrate several examples.
  • nasolacrimal stenosis nasolacrimal stenosis, chemotherapy induced ocular toxicity, lacrimal duct stenosis, punctal stenosis, lacrimation, abnormal lacrimation (such as keratoconjunctivitis sicca), increased tearing, nasolacrimal blockage, keratitis, keratoconjunctivitis, conjunctivitis, or a combination thereof may be prevented or treated.
  • Also contemplated is a method comprising administering cyclosporin A topically to the eye of a person, wherein docetaxel is also administered to said person, wherein said method is effective in preventing or treating an ocular condition associated with the administration of docetaxel.
  • the ocular condition may be associated with any antiviral agent, the following
  • the ocular condition may be associated with any chemotherapy agent, the following
  • Derivatives of paclitaxel generally include the macrocycle shown below, where derivatives are formed at a hydroxyl moiety.
  • Chemotherapeutic compounds incorporating this structure are thus contemplated.
  • the structures of paclitaxel and docetaxel are shown below.
  • the chemotherapy agent is docetaxel.
  • the ocular condition may be associated with any immunomodulator, the following
  • therapeutically active agents may cause lacrimal duct stenosis:
  • one or more of the ocular conditions disclosed herein may be associated with the following therapeutically active agents: abacavir sulfate, amantadine hydrochloride, amphotericin B, basiliximab, bexarotene, capecitabine, cetuximab, delavirdine mesylate, docetaxel, doxorubicin hydrochloride, enfuvirtide, epirubicin hydrochloride, erlotinib, fluorouracil, gefitinib, glatiramer acetate, imatinib mesylate, imiquimod, interferon alfa-2b, irinotecan hydrochloride, ivermectin, lamivudine, lamotrigine, leflunomide, mycophenolate mofetil, mycophenolate mofetil hydrochloride, nevirapine, oseltamivir phosphate, oxaliplatin, palivi
  • the therapeutically active agent is administered in the usual manner known in the art for the condition being treated.
  • a therapeutically active agent and cyclosporin A may be administered in a single composition.
  • compositions are disclosed in the following patent applications, each of which is expressly incorporated by reference herein: U.S. Patent application Ser. No. 11/181, 409, filed on Jul. 13, 2005; U.S. Patent application Ser. No. 11/181, 509, filed on Jul. 13, 2005; U.S. Patent application Ser. No. 11/181, 187, filed on Jul. 13, 2005; U.S. Patent application Ser. No. 11/181, 178, filed on Jul. 13, 2005; U.S. Patent application Ser. No. 11/181, 428, filed on Jul. 13, 2005; U.S. Patent application Ser. No. 11/255,821, filed on Oct. 19, 2005; U.S. Patent application Ser. No. 11/161,218, filed on July 27, 2005; and U.S. Provisional Patent Application Ser. No. 60/727,684, filed on Oct. 17, 2005.
  • cyclosporin A is administered in the form of Restasis®, available from Allergan, Inc.
  • the cyclosporin A is administered twice a day as indicated on the package insert.

Abstract

Therapeutic methods are disclosed herein.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This continuation application claims priority to: U.S. Provisional Patent Application No. 60/596,709, filed on Oct. 14, 2005; U.S. Provisional Patent Application No. 60/597,431, filed on Nov. 30, 2005; U.S. Provisional Patent Application, No. 60/805,577, filed on Jun. 22, 2006; U.S. patent application Ser. No. 11/548,631, filed Oct. 11, 2006, now U.S. Pat. No. 7,745,400; U.S. patent application Ser. No. 12/825,116, filed Jun. 28, 2010, now U.S. Pat. No. 8,501,1 74; and co-pending U.S. patent application Ser. No. 13/957,722, filed Aug. 2, 2013, all of which are expressly incorporated by reference herein.
    • DESCRIPTION OF THE INVENTION
  • Patients undergoing treatment with certain therapeutically active agents can have certain ocular conditions as a result of that treatment. In particular, patients undergoing chemotherapy with a therapeutically active agent effective for treatment of a cancer often have ocular conditions as a result of that treatment.
  • One embodiment is a method comprising administering a cyclosporin, an analog or derivative thereof, or a combination thereof, to an eye of a mammal in combination with administration of a therapeutically active agent to said mammal, said therapeutically active agent being an chemotherapy agent or an antiviral agent, wherein said method is effective in preventing or treating an ocular condition associated with the use of said therapeutically active agent.
  • “Administration of a therapeutically active agent to said mammal” means administration of the therapeutically active agent to the mammal in any way that a therapeutically active agent may be administered. Thus, administration of the therapeutically active agent is not limited to the eye, but may include systemic administration via oral, intravenous, rectal, or other means; or administration locally to any part of the body by injection, implantation, topical administration, or other means.
  • Administration of the therapeutically active agent need not exactly overlap in time with the administration of the cyclosporin, an analog or derivative thereof, or a combination thereof. For example, the cyclosporin, analog or derivative thereof, or a combination thereof might be administered to a mammal before the mammal receives any of the therapeutically active agent to avoid the onset of the ocular condition. In another example, the cyclosporin, analog or derivative thereof, or a combination thereof, might be administered after the mammal has begun to receive the therapeutically active agent. In another example, the cyclosporin, analog or derivative thereof, or a combination thereof, might be administered after the mammal has ceased receiving the therapeutically active agent. Administration of the cyclosporin, analog or derivative thereof, or a combination thereof might also be simultaneous with the administration of the therapeutically active agent. Thus, any time relationship may exist between the mammal receiving the therapeutically active agent and the cyclosporin, analog or derivative thereof, or a combination thereof, provided that the use of the latter is reasonably related to treatment or prophylaxis of a condition associated with the former.
  • It may be convenient to provide a single pharmaceutical composition which comprises both (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent when the agents are to be administered simultaneously.
  • It may be convenient to provide (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent in form of a kit. For example, the agents may be packaged together. For example, (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent may each be packaged in conventional pharmaceutical packaging such as boxes, jars, blister packs, vials, bottles, syringes etc., and the individually packaged components may then be combined to form a kit e.g. by the use of further packaging such as a box, or by joining up the individual packages. When in kit form, the agents can be taken independently of one another, thus allowing the user freedom to decide the temporal relationship between his use of each of the agents.
  • Use of a cyclosporin, or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person undergoing treatment with a therapeutically active agent for the treatment of cancer is contemplated. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of a chemotherapy agent.
  • Also contemplated is use of a cyclosporin, or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person who is undergoing treatment with an antiviral agent. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of an antiviral agent.
  • Also contemplated is use of a cyclosporin, or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person who is undergoing treatment with an immunomodulator. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of an immunomodulator.
  • Figure US20140010846A1-20140109-C00001
  • Cyclosporin A is a cyclic peptide with immunosuppressive properties having the structure shown above. It is also known by other names including cyclosporine, cyclosporine A, ciclosporin, and ciclosporin A.
  • Other cyclosporins include cyclosporine b, cyclosporine D, cyclosporine G, which are well known in the art. Cyclosporin derivatives and analogs are also known in the art. For example, U.S. Pat. Nos. 6,254,860 and 6,350,442, incorporated by reference herein, illustrate several examples.
  • The ocular conditions to be prevented or treated are well known in the art. In particular, nasolacrimal stenosis, chemotherapy induced ocular toxicity, lacrimal duct stenosis, punctal stenosis, lacrimation, abnormal lacrimation (such as keratoconjunctivitis sicca), increased tearing, nasolacrimal blockage, keratitis, keratoconjunctivitis, conjunctivitis, or a combination thereof may be prevented or treated.
  • Also contemplated is a method comprising administering cyclosporin A topically to the eye of a person, wherein docetaxel is also administered to said person, wherein said method is effective in preventing or treating an ocular condition associated with the administration of docetaxel.
  • Although the ocular condition may be associated with any antiviral agent, the following
      • antiviral agents are contemplated in particular:
      • Zalcitabine, and
      • Rimantadine Hydrochloride.
  • Although the ocular condition may be associated with any chemotherapy agent, the following
      • chemotherapy agents are contemplated in particular:
      • Paclitaxel and derivatives thereof, such as Docetaxel
      • Doxorubicin Hydrochloride,
      • Irinotecan Hydrochloride,
      • Fluorouracil,
      • Imatinib Mesylate, and
      • Rituximab.
  • Derivatives of paclitaxel generally include the macrocycle shown below, where derivatives are formed at a hydroxyl moiety.
  • Figure US20140010846A1-20140109-C00002
  • Chemotherapeutic compounds incorporating this structure are thus contemplated. For example, the structures of paclitaxel and docetaxel are shown below.
  • Figure US20140010846A1-20140109-C00003
  • In one embodiment, the chemotherapy agent is docetaxel.
  • Although the ocular condition may be associated with any immunomodulator, the following
      • immunomodulators are contemplated in particular:
      • Interferon alfa-2b, Recombinant
      • Mycophenolate Mofetil, and
      • Mycophenolate Mofetil Hydrochloride.
  • While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause lacrimal duct stenosis:
      • docetaxel.
  • While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause lacrimation:
      • interferon alfa-2b, recombinant,
      • doxorubicin hydrochloride,
      • irinotecan hydrochloride,
      • fluorouracil,
      • docetaxel, and
      • zalcitabine.
  • While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause abnormal lacrimation:
      • mycophenolate motefil,
      • mycophenolate motefil hydrochloride,
      • imatinib mesylate,
      • ritumixab, and
      • rimantadine hydrochloride.
  • While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause keratitis:
      • Amantadine Hydrochloride,
      • Erlotinib,
      • Bexarotene, and
      • Voriconazole.
  • While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause keratoconjunctivitis:
      • Capecitabine.
  • While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause conjunctivitis:
      • Risedronate Sodium,
      • Leflunomide,
      • Mycophenolate Mofetil,
      • Oxaliplatin,
      • Cetuximab,
      • Ribavirin,
      • Rituximab,
      • Basiliximab,
      • Erlotinib,
      • Capecitabine,
      • Doxorubicin Hydrochloride,
      • Imiquimod,
      • Amphotericin B, liposomal,
      • Zolpidem Tartrate,
      • Glatiramer Acetate,
      • Epirubicin Hydrochloride,
      • Saquinavir,
      • Enfuvirtide,
      • Imatinib Mesylate,
      • Gefitinib,
      • Lamotrigine,
      • Delavirdine Mesylate,
      • Rituximab,
      • Ivermectin,
      • Palivizumab,
      • Oseltamivir Phosphate,
      • Bexarotene,
      • Docetaxel,
      • Abacavir Sulfate,
      • Lamivudine,
      • Zidovudine,
      • Voriconazole,
      • Nevirapine,
      • Ribavirin, and
      • Abacavir Sulfate.
  • Additionally, one or more of the ocular conditions disclosed herein may be associated with the following therapeutically active agents: abacavir sulfate, amantadine hydrochloride, amphotericin B, basiliximab, bexarotene, capecitabine, cetuximab, delavirdine mesylate, docetaxel, doxorubicin hydrochloride, enfuvirtide, epirubicin hydrochloride, erlotinib, fluorouracil, gefitinib, glatiramer acetate, imatinib mesylate, imiquimod, interferon alfa-2b, irinotecan hydrochloride, ivermectin, lamivudine, lamotrigine, leflunomide, mycophenolate mofetil, mycophenolate mofetil hydrochloride, nevirapine, oseltamivir phosphate, oxaliplatin, palivizumab, ribavirin, rimantadine hydrochloride, risedronate sodium, rituximab, saquinavir, voriconazole, zalcitabine, zidovudine, and zolpidem tartrate.
  • The therapeutically active agent is administered in the usual manner known in the art for the condition being treated.
  • Alternatively, a therapeutically active agent and cyclosporin A may be administered in a single composition.
  • Useful compositions are disclosed in the following patent applications, each of which is expressly incorporated by reference herein: U.S. Patent application Ser. No. 11/181, 409, filed on Jul. 13, 2005; U.S. Patent application Ser. No. 11/181, 509, filed on Jul. 13, 2005; U.S. Patent application Ser. No. 11/181, 187, filed on Jul. 13, 2005; U.S. Patent application Ser. No. 11/181, 178, filed on Jul. 13, 2005; U.S. Patent application Ser. No. 11/181, 428, filed on Jul. 13, 2005; U.S. Patent application Ser. No. 11/255,821, filed on Oct. 19, 2005; U.S. Patent application Ser. No. 11/161,218, filed on July 27, 2005; and U.S. Provisional Patent Application Ser. No. 60/727,684, filed on Oct. 17, 2005.
  • In one embodiment, cyclosporin A is administered in the form of Restasis®, available from Allergan, Inc. The cyclosporin A is administered twice a day as indicated on the package insert.
  • Although there has been hereinabove described pharmaceutical compositions for the purpose of illustrating the manner in which the invention may be used to advantage, it should be appreciated that the invention is not limited thereto. Accordingly, any and all modifications, variations, or equivalent arrangements, which may occur to those skilled in the art, should be considered to be within the scope of the present invention as defined in the appended claims.

Claims (9)

1-11. (canceled)
12. A method comprising administering an ophthalmically acceptable emulsion comprising cyclosporin A to a mammal that has ceased receiving a therapeutically active agent, wherein the therapeutically active agent comprises rimantadine hydrochloride, and wherein the method is effective in treating abnormal lacrimation.
13. The method of claim 12, wherein the ophthalmically acceptable emulsion comprises cyclosporin A at a concentration of about 0.05%.
14. The method of claim 13, wherein the ophthalmically acceptable emulsion further comprises castor oil, polysorbate 80, and high molecular weight co-polymers of acrylic acid and a long chain alkyl methacrylate cross-linked with allyl ethers of pentaerythritol.
15. The method of claim 13, wherein the abnormal lacrimation is associated with keratoconjunctivitis.
16. The method of claim 13, wherein the abnormal lacrimation is the result of keratoconjunctivitis.
17. The method of claim 15, wherein the keratoconjunctivitis is associated with the therapeutically active agent.
18. The method of claim 16, wherein the keratoconjunctivitis is associated with the therapeutically active agent.
19-24. (canceled)
US13/966,744 2005-10-14 2013-08-14 Prevention and treatment of ocular side effects with a cyclosporin Abandoned US20140010846A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/966,744 US20140010846A1 (en) 2005-10-14 2013-08-14 Prevention and treatment of ocular side effects with a cyclosporin

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US59670905P 2005-10-14 2005-10-14
US59743105P 2005-11-30 2005-11-30
US80550906P 2006-06-22 2006-06-22
US80557706P 2006-06-22 2006-06-22
US11/548,631 US7745400B2 (en) 2005-10-14 2006-10-11 Prevention and treatment of ocular side effects with a cyclosporin
US12/825,116 US8501174B2 (en) 2005-10-14 2010-06-28 Prevention and treatment of ocular side effects with a cyclosporin
US13/957,722 US20140030226A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin
US13/966,744 US20140010846A1 (en) 2005-10-14 2013-08-14 Prevention and treatment of ocular side effects with a cyclosporin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/957,722 Continuation US20140030226A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin

Publications (1)

Publication Number Publication Date
US20140010846A1 true US20140010846A1 (en) 2014-01-09

Family

ID=38263959

Family Applications (7)

Application Number Title Priority Date Filing Date
US11/548,631 Active US7745400B2 (en) 2005-10-14 2006-10-11 Prevention and treatment of ocular side effects with a cyclosporin
US12/825,116 Active 2027-06-08 US8501174B2 (en) 2005-10-14 2010-06-28 Prevention and treatment of ocular side effects with a cyclosporin
US13/957,722 Abandoned US20140030226A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin
US13/957,796 Abandoned US20140038904A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin
US13/957,772 Abandoned US20130345147A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin
US13/966,770 Abandoned US20140011751A1 (en) 2005-10-14 2013-08-14 Prevention and treatment of ocular side effects with a cyclosporin
US13/966,744 Abandoned US20140010846A1 (en) 2005-10-14 2013-08-14 Prevention and treatment of ocular side effects with a cyclosporin

Family Applications Before (6)

Application Number Title Priority Date Filing Date
US11/548,631 Active US7745400B2 (en) 2005-10-14 2006-10-11 Prevention and treatment of ocular side effects with a cyclosporin
US12/825,116 Active 2027-06-08 US8501174B2 (en) 2005-10-14 2010-06-28 Prevention and treatment of ocular side effects with a cyclosporin
US13/957,722 Abandoned US20140030226A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin
US13/957,796 Abandoned US20140038904A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin
US13/957,772 Abandoned US20130345147A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin
US13/966,770 Abandoned US20140011751A1 (en) 2005-10-14 2013-08-14 Prevention and treatment of ocular side effects with a cyclosporin

Country Status (2)

Country Link
US (7) US7745400B2 (en)
TW (1) TW200735886A (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140011750A1 (en) * 2005-10-14 2014-01-09 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
AU2008310956B2 (en) * 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US20110009339A1 (en) * 2009-04-14 2011-01-13 Allergan, Inc Method of treating blurred vision and other conditions of the eye with cyclosporin compositions
CN102458370A (en) 2009-06-09 2012-05-16 卢克斯生物科技公司 Topical drug delivery systems for ophthalmic use
GB201514328D0 (en) * 2015-08-12 2015-09-23 Sigmoid Pharma Ltd Compositions
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445174B (en) 1978-03-07 1986-06-09 Sandoz Ag PHARMACEUTICAL COMPOSITION CONTAINING A CYCLOSPORIN AND A HEALING SUBSTANCE
US4388229A (en) 1981-11-02 1983-06-14 Syntex (U.S.A.) Inc. Contact lens rejuvenating solution
US4533594A (en) 1983-12-16 1985-08-06 Porritts & Spencer Batt-on-mesh felt employing polyurethane-coated multifilaments in the cross-machine direction
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4814323A (en) 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
JP2577049B2 (en) 1987-06-04 1997-01-29 三共株式会社 Cyclosporine preparation
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
JPH0667850B2 (en) * 1987-09-03 1994-08-31 ユニバーシティ オブ ジョージア リサーチ ファウンデーション，インコーポレイテッド Ophthalmic cyclosporin composition
HU201567B (en) 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US6007840A (en) 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US7081445B2 (en) 1989-02-20 2006-07-25 Novartis Ag Cyclosporin galenic forms
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5294604A (en) 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
CA2048302A1 (en) 1990-08-15 1992-02-16 Victoria P. Meucci Solubilization reagent for biological test samples
MA22456A1 (en) 1991-03-05 1992-10-01 Procter & Gamble PERSONAL CLEANING PRODUCT OF THE SOFT, STABLE LIQUID SOAP TYPE AND METHOD FOR THE PREPARATION THEREOF
IL102236A0 (en) 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
JP3631490B2 (en) 1992-05-13 2005-03-23 ノバルティス ファーマ株式会社 Cyclosporine-containing ophthalmic composition
PT589843E (en) 1992-09-25 2002-04-29 Novartis Ag PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLOSPORTS
US20020107183A1 (en) 1993-04-20 2002-08-08 Monika Petszulat Pharmaceutical preparations comprising cyclosporin for oral administration
CH686761A5 (en) 1993-05-27 1996-06-28 Sandoz Ag Pharmaceutical formulations.
US20020099067A1 (en) 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
DE4340781C3 (en) 1993-11-30 2000-01-27 Novartis Ag Liquid preparations containing cyclosporin and process for their preparation
US5891846A (en) 1994-02-17 1999-04-06 Shiseido Company, Ltd. Cyclosporin-containing emulsion composition
KR0146671B1 (en) 1994-02-25 1998-08-17 김충환 Cyclosporin-containing powder composition
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US5827835A (en) 1994-08-30 1998-10-27 Alcon Laboratories, Inc. Thermally-gelling emulsions
ES2177652T3 (en) 1994-11-03 2002-12-16 Novartis Ag NEW FORMS OF PREPARATION OF CYCLOSPORINE FOR ORAL APPLICATION WITH SIMPLE COMPOSITION AND HIGH BIODISPONIBILITY, AND PROCEDURE FOR OBTAINING IT.
KR0167613B1 (en) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 Cyclosporin-containing soft capsule compositions
US5827822A (en) 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5834017A (en) 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5962019A (en) 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE19544507B4 (en) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin containing preparations
US6787306B1 (en) * 1996-03-20 2004-09-07 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for detecting dihydropyrimidine dehydrogenase splicing mutations
US5753166A (en) 1996-04-29 1998-05-19 Eastman Chemical Company Process of making a non-circular cross-sectional fiber
US5798333A (en) 1996-09-17 1998-08-25 Sherman; Bernard C. Water-soluble concentrates containing cyclosporins
WO1998033512A1 (en) 1997-01-30 1998-08-06 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin a
FR2762843B1 (en) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NZ328751A (en) 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
EP1042341A1 (en) * 1997-11-25 2000-10-11 Protarga Inc. Nucleoside analog compositions and uses thereof
JP4761093B2 (en) 1997-12-10 2011-08-31 シクロスポリン セラポイティクス リミテッド Pharmaceutical composition comprising omega-3 fatty acid oil
TWI241915B (en) 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
KR100336090B1 (en) 1998-06-27 2002-05-27 윤승원 Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof
IL141155A0 (en) * 1998-07-30 2002-02-10 Human Rt Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
DE19835906A1 (en) 1998-08-07 2000-02-10 Basf Ag Process for the production of vinyl compounds
EP1135150B1 (en) 1998-12-11 2012-10-17 Tris Pharma, Inc. Self-emulsifying compositions for drugs poorly soluble in water
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6057289A (en) 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
EP1227793A1 (en) 1999-11-02 2002-08-07 Cipla Ltd. Cyclosporin formulation
DE19958684A1 (en) * 1999-12-06 2001-06-07 Knoll Ag Use of GD3 synthase inhibitors for the treatment of neuropathological disorders and methods for the identification of GD3 synthase inhibitors
GB0007907D0 (en) 2000-03-31 2000-05-17 Merck Sharp & Dohme Therapeutic agents
ATE250924T1 (en) 2000-04-07 2003-10-15 Medidom Lab EYE MEDICINAL CONTAINING CYCLOSPORINE, HYALURONIC ACID AND POLYSORBATES
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CN1127955C (en) 2000-07-07 2003-11-19 中山医科大学中山眼科中心 Medicine for treating immune relative disease of anterior chamber and surface of eye
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
AR033711A1 (en) 2001-05-09 2004-01-07 Novartis Ag PHARMACEUTICAL COMPOSITIONS
US6656460B2 (en) 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
ITMI20012694A1 (en) 2001-12-19 2003-06-19 Remedia S R L PHARMACEUTICAL COMPOSITION INCLUDING A DOUBLE OIL / WATER / OIL MICROEMULSION INCORPORATED IN A SOLID SUPPORT
CA2471241A1 (en) 2001-12-20 2003-07-03 Bernard Charles Sherman Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
KR100441167B1 (en) 2001-12-27 2004-07-21 씨제이 주식회사 Composition of microemulsion preconcentrate
KR20030065831A (en) 2002-02-01 2003-08-09 주식회사 태평양 cyclosporin-containing sustained release pharmaceutical composition
US20030225011A1 (en) * 2002-05-31 2003-12-04 Samuel David Phospholipase A2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease
GB2391471B (en) 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
GB2391473B (en) 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
GB2391472B (en) 2002-08-02 2004-12-08 Satishchandra Punambhai Patel Pharmaceutical compositions
AU2003277424A1 (en) * 2002-10-17 2004-05-04 New York University Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20050196370A1 (en) 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20040185068A1 (en) 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20050043258A1 (en) * 2003-03-26 2005-02-24 Genteric, Inc. Methods of treating xerostomia and xerophthalmia
WO2004091578A2 (en) 2003-04-09 2004-10-28 Biodelivery Sciences International, Inc. Novel encochleation methods, cochleates and methods of use
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
AR047988A1 (en) * 2004-03-11 2006-03-15 Wyeth Corp ANTI -OPLASTIC COMBINATIONS OF CCI-779 AND RITUXIMAB
JP2008506681A (en) * 2004-07-16 2008-03-06 ファイザー・プロダクツ・インク Combination therapy for non-blood malignant tumors using anti-IGF-1R antibody
US8541461B2 (en) * 2005-06-23 2013-09-24 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
WO2008000085A1 (en) 2006-06-30 2008-01-03 The University Of Western Ontario Process for producing a concrete additive from an agricultural residue
US8536190B2 (en) * 2007-01-30 2013-09-17 Allergan, Inc. Treating unwanted ocular conditions using an ascomycin macrolactam

Also Published As

Publication number Publication date
US20070167358A1 (en) 2007-07-19
US20140011751A1 (en) 2014-01-09
TW200735886A (en) 2007-10-01
US20130345147A1 (en) 2013-12-26
US20140038904A1 (en) 2014-02-06
US7745400B2 (en) 2010-06-29
US20140030226A1 (en) 2014-01-30
US8501174B2 (en) 2013-08-06
US20100266622A1 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
US20140010846A1 (en) Prevention and treatment of ocular side effects with a cyclosporin
US9156886B2 (en) Cyclosporin analogues for preventing or treating hepatitis C infection
US8481483B2 (en) Cyclosporin analogues
US20110206637A1 (en) Antiviral agents
NO334908B1 (en) Pharmaceutical preparation for the treatment of optic neuritis and its use.
US8349312B2 (en) Proline substituted cyclosporin analogues
US7696165B2 (en) Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US20110008285A1 (en) Novel cyclosporin analogues
US8236778B2 (en) Synergistic 5′-methylthioadenosine combinations
US8685917B2 (en) Cyclosporin analogues
KR20010022572A (en) Product Comprising at Least a Double Stranded RNA Combined with at Least an Antiviral Agent
US20130345148A1 (en) Prevention and treatment of ocular side effects with a cyclosporin
US10610565B2 (en) Prevention and treatment of ocular side effects with a cyclosporin
US20140011750A1 (en) Prevention and treatment of ocular side effects with a cyclosporin
US20140011752A1 (en) Prevention and treatment of ocular side effects with a cyclosporin
US8906853B2 (en) [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
WO2013148155A1 (en) Compositions and methods for the treatment of dry eye disease
AU2013200652A1 (en) Cyclosporin analogues for preventing or treating hepatitis C infection

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALLERGAN, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FEINERMAN, GREGG;BARTH, NEIL;SCHIFFMAN, RHETT;AND OTHERS;SIGNING DATES FROM 20060911 TO 20061019;REEL/FRAME:032082/0619

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: SAINT REGIS MOHAWK TRIBE, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALLERGAN, INC.;REEL/FRAME:043830/0446

Effective date: 20170908